Gent, Belgium
September 12, 2008
Regulatory release
Devgen NV (Euronext Brussels: DEVG) publishes required
information in accordance with new transparency legislation
(Belgian Act of May 2, 2007) on disclosure of major holdings in
issuers whose shares are admitted to trading on a regulated
Belgian market.
Status as of 1 September 2008
Basic data
Total capital: 1 341 110.15 EUR
Total number of securities conferring voting rights: 17 881 500
shares
Total number of voting rights (the denominator): 17 881 500 (one
voting right per share)
Supplementary data
Total number of bonds convertible into securities conferring
voting rights: zero
Total number of outstanding warrants convertible into securities
conferring voting rights: 1 350 790
Total number of voting rights that may result form the exercise
of outstanding warrants: 1 350 790
Total number of shares without voting rights: zero
Notification thresholds set by the Articles of Association
According to article 14 of The Articles of Association of Devgen
NV, the provisions relating to the compulsory transparency
declarations apply not only to the legal thresholds of 5% and of
each multiple of 5%, but also to the threshold of 3%.
Information concerning the transparency legislation
Detailed information concerning the transparency legislation can
be found in the Extract from the "Guide to the Transparency
Legislation CBFA_2008_16 of 8 July 2008" which is available from
the website of the Banking, Finance and Insurance Commission
(CBFA): www.cbfa.be/eng/gv/ah/circ/pdf/cbfa_2008_16.pdf
For submitting the notifications the CBFA recommends the use of
its standard form TR-1 BE, which is also available from the CBFA
website: www.cbfa.be/eng/gv/ah/circ/pdf/TR-1BE.xls
The notifications should be transmitted to both Devgen and the
CBFA. The CBFA recommends transmitting the notifications first
electronically, to the e-mail address trp.fin@cbfa.be, and
subsequently - for reasons of legal certainty - by fax to number
+ 32 2 220 59 12.
It is recommended to transmit notifications to Devgen NV by
email to the attention of:
Wim Goemaere, CFO
E-mail address: ir@Devgen.com
Fax: +32 9 324 24 25
About Devgen
Devgen is a public agricultural biotech and seed company focused
on developing and commercializing:
• biotech traits and hybrid seeds to meet the growing needs for
high yielding, high quality hybrid rice, sorghum, millet and
sunflower of the Indian and other south-east Asian markets;
• a novel generation of biotech products to protect a wide
spectrum of crops incurred from pests; to render crops more
tolerant against stress factors such as drought and salty soils
and to decrease the need for fertilizer use by optimizing
nitrogen uptake;
• a new generation of agrochemical products to protect crops
from damage inflicted by plant parasitic nematodes.
Incorporated in 1997, Devgen has offices in Ghent (Belgium),
Singapore, Hyderabad (India) and Delaware (US) and employs more
than 180 people worldwide. Devgen is listed on Euronext Brussels
(ticker: DEVG) since June 2005. |
|
